The outcome predictors in IBD trials usually include DAI, C-reactive protein (CRP), rapid fecal calprotectin (FC), the Mayo score and the Crohn’s Disease Activity Index (CDAI), and the correct interpretation of the results relies on quality preparation for colonoscopy [81,82,83]. This evidence concerns the gene CRP and irritable bowel syndrome.